Alnylam Pharmaceuticals
ALNY
#630
Rank
ยฃ25.83 B
Marketcap
ยฃ200.29
Share price
-1.16%
Change (1 day)
38.35%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2023 (TTM): -ยฃ3.30

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is -ยฃ3.34. In 2022 the company made an earnings per share (EPS) of -ยฃ7.56 a decrease over its 2021 EPS that were of -ยฃ5.86.

EPS history for Alnylam Pharmaceuticals from 2003 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-ยฃ3.30-56.28%
2022-ยฃ7.5629.03%
2021-ยฃ5.86-3.36%
2020-ยฃ6.06-8.48%
2019-ยฃ6.627.67%
2018-ยฃ6.1539.74%
2017-ยฃ4.4012.94%
2016-ยฃ3.9038.84%
2015-ยฃ2.81-32.88%
2014-ยฃ4.18259.44%
2013-ยฃ1.16-31.25%
2012-ยฃ1.6952.94%
2011-ยฃ1.1130.77%
2010-ยฃ0.85-8.77%
2009-ยฃ0.9378.13%
2008-ยฃ0.52-70.78%
2007-ยฃ1.7899.09%
2006-ยฃ0.89-43.88%
2005-ยฃ1.59-82.33%
2004-ยฃ9.02-59.23%
2003-ยฃ22.13

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-ยฃ1.38-58.64%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ30.38-1,009.00%๐Ÿ‡บ๐Ÿ‡ธ USA
-ยฃ6.37 90.51%๐Ÿ‡บ๐Ÿ‡ธ USA
-ยฃ0.22-93.43%๐Ÿ‡บ๐Ÿ‡ธ USA
-ยฃ1.37-58.88%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ3.04-191.00%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
ยฃ2.59-177.38%๐Ÿ‡ซ๐Ÿ‡ท France
-ยฃ1.63-51.34%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel